NSE: INDOCO | BSE: 532612

Slowing Down Stock

Download real time

230.41 -0.58 (-0.25%)

40.55% Fall from 52W High

10,871 NSE+BSE Volume

NSE 29 Apr, 2025 11:20 AM (IST)

2,125.5

Market Cap

Above industry Median

0.7

Beta 1Year

Very Low volatility

Indoco Remedies Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for INDOCO, BSE:532612 Indoco Remedies Ltd.

Indoco Remedies Ltd.

19 May 2022

230.41

-0.25%

Indoco Remedies

Buy: Indoco Remedies Ltd.

Yes Securities

Indoco Remedies Ltd. has lost -29.88% in the last 1 Year

Indoco Remedies Ltd.

18 May 2022

230.41

-0.25%

Indoco Remedies

Buy: Indoco Remedies Ltd.

ICICI Direct

Indoco Remedies Ltd. has lost -23.79% in the last 6 Months

Indoco Remedies Ltd.

03 Feb 2022

230.41

-0.25%

INDOCO REMEDIES LTD

Accumulate: Indoco Remedies Ltd.

Target

Prabhudas Lilladhar

Indoco Remedies' (INDR) reported another muted quarter in a regulated market performance; management expects to recover in coming quarters given strong order book and new launches. Domestic market continued to witnessed growth on low base in therapies like anti-infective, GI, VMN and Opthal. We remain structurally positive on INDR on account of 1) MR productivity enhancement and higher penetration in North and East markets 2) new launches in US and 3) higher tender business in EU market. This will...

Indoco Remedies Ltd. is trading below all available SMAs

Indoco Remedies Ltd.

03 Feb 2022

230.41

-0.25%

Indoco Remedies

Buy: Indoco Remedies Ltd.

Target

ICICI Securities Limited

Formulation exports accounted for 40% (regulated markets:81%) of revenues while APIs contributed 8% with remaining coming from CRAMS Q3FY22 Results: Indoco reported revenue growth due to traction in domestic...

Indoco Remedies Ltd. has lost -29.88% in the last 1 Year

Indoco Remedies Ltd.

04 Nov 2021

230.41

-0.25%

Q2FY22 Result Update - Strong domestic show; Regulated markets to recover in H2 - ACCUMULATE

Accumulate: Indoco Remedies Ltd.

Recommendation Target

Prabhudas Lilladhar

Domestic formulation continues to register strong growth Indoco Remedies' (INDR) Q2FY22 performance was muted in regulated market, but should recover with pick up in profit share from Brinzolamide in US and settling of logistics issues in EU markets. The domestic market continued to witnessed strong growth in therapies like anti-infective, GI, VMN and Opthal. We remain structurally positive on INDR on account of 1) MR productivity enhancement and higher penetration in North and East markets 2) new launches in US and 3) higher tender business in EU market. This will...

Indoco Remedies Ltd. has an average target of 320.00 from 2 brokers.

Indoco Remedies Ltd.

03 Nov 2021

230.41

-0.25%

Indoco Remedies

Buy: Indoco Remedies Ltd.

ICICI Securities Limited

Indoco Remedies Ltd. has lost -29.88% in the last 1 Year

Indoco Remedies Ltd.

12 Aug 2021

230.41

-0.25%

Q1FY22 Result Update - US, India offer double pivot for growth; Tailwind in acute therapy to have booster effect in FY22E - BUY

Buy: Indoco Remedies Ltd.

Target

Prabhudas Lilladhar

last eight quarters. INDR maintains robust guidance in US generics with growth of 67%/24% in FY22E/FY23E. Its business expansion will drive 25%+ growth in Europe. We note that India formulation sales growth of more than 17% with revenue contribution of 55-60% will have multiplier benefit on sales and headline margins going forward. This along with strong and sustainable growth in US will improve EBITDA margin from 15-16% to 18-20% in FY22E23E. We maintain our positive outlook on INDR as we believe that 1) MR productivity would improve to Rs3lakhs/month (from Rs2.5lakh/month) along with existing field force, 2) India formulations growth to return to more than...

Indoco Remedies Ltd. has lost -29.88% in the last 1 Year

Indoco Remedies Ltd.

12 Aug 2021

230.41

-0.25%

Indoco Remedies

Buy: Indoco Remedies Ltd.

Target

ICICI Securities Limited

Indoco Remedies Ltd. has lost -23.79% in the last 6 Months

Indoco Remedies Ltd.

26 May 2021

230.41

-0.25%

Q4FY21 Result Update - Covid impacts FY21; outlook remains strong - BUY

Buy: Indoco Remedies Ltd.

Target

Prabhudas Lilladhar

Rs3.1bn for FY23E, with strong India formulations growth. We revise our earnings estimate by downward by 2.6% for FY22E due to tepid performance of acute therapy medicines in IPM given the 2nd wave of pandemic. While, we increased estimates for FY23E by 2.5% in FY23E on back of increase in EUs growth projection. INDR's 3QFY21 revenue and PAT missed our estimates, due to sharper decline in India formulations and API...

Indoco Remedies Ltd. has lost -29.88% in the last 1 Year

Indoco Remedies Ltd.

26 May 2021

230.41

-0.25%

Indoco Remedies

Buy: Indoco Remedies Ltd.

ICICI Securities Limited

Q4 growth was led by strong growth in export markets (albeit on lower base) and lower staff, travel & promotional costs. The management expects 80-90 bps margin improvement in FY22 to ~19%. After going through rough patches in FY18-20, where Indoco faced headwinds on the domestic front (structural issues, pandemic) and exports front (regulatory setbacks), the situation is returning to normalcy. Indoco is expected to post strong FY22 topline growth as domestic sales normalise and grow amid opportunities arising out of post-Covid complications. Export formulations are also...

Indoco Remedies Ltd. has an average target of 320.00 from 2 brokers.

Is Indoco Remedies Ltd. worth buying?

58 Votes:

Buy 74.14%

Sell 15.52%

Hold 10.34%

RESEARCH REPORTS

Not Rated SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf